BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//wp-events-plugin.com//7.2.3.1//EN
TZID:Europe/Helsinki
X-WR-TIMEZONE:Europe/Helsinki
BEGIN:VEVENT
UID:186914@bioscience.fi
DTSTART;TZID=Europe/Helsinki:19700101T000000
DTEND;TZID=Europe/Helsinki:19700101T000000
DTSTAMP:20260417T112539Z
URL:
SUMMARY:Immunology Seminar: Carlos Rogério Figueiredo
DESCRIPTION:February 4th at 14-15 (Finland time)\n\nVirtual event\n\nFlyer\
 n\nDr.  Carlos Rogério Figueiredo\, University of Turku: New Mechanisms 
 of Immunosuppression in Melanoma: Implications for Rational Immunotherapy 
 Innovation\n\nRegister for the Immunology Seminar Series email list to get
  calendar invitation to the online seminar: https://link.webropolsurveys.c
 om/S/D29C32AA6E8A2F7A\n\nHost: Professor Riitta Lahesmaa ( rilahes@utu.fi 
 )\n\nImmunology seminar series is jointly organised by the Finnish Society
  for Immunology\, InFLAMES Flagship and Turku Bioscience. For further info
 rmation contact Anne Lahdenperä  ( ankahy@utu.fi ) or Riitta Lahesmaa ( 
 rilahes@utu.fi )\, University of Turku.\n\n***\n\nDr. Carlos Rogério Figu
 eiredo is a Principal Investigator and Docent of Immunology at the Univers
 ity of Turku\, with a focus on cancer immunology and resistance to immunot
 herapy. Rogerio did his PhD in Immunology &amp\; Microbiology in the Feder
 al University of São Paulo\, Brazil\, in 2015. Postdoctoral Fellowships R
 ogerio did in translational oncology in the University of Liverpool and in
  Immuno-oncology in the University of Turku. His research explores the mol
 ecular mechanisms underlying immunosuppression\, leading to cold tumor for
 mation and poor responses to current immunotherapies. As the leader of the
  Medical Immuno-Oncology Research Group (MIORG) in Finland\, he conducts i
 ntegrative multi-omic studies to identify novel biomarkers to advance prog
 nostication tools and evaluate their functional roles in antitumor immune 
 responses. This work supports evidence-based insights for rational immunot
 herapy innovation\, with a primary focus on cutaneous and ocular melanoma 
 models. Rogerio is the winner of Scandinavian Society for Immunology (SSI)
  Young Investigator Award year 2024.\n\nSelected publications:\n\n1) Figue
 iredo CR\, Azevedo RA\, Mousdell S\, Resende-Lara PT\, Ireland L\, Santos 
 A\, Girola N\, Cunha RLOR\, Schmid MC\, Polonelli L\, Travassos LR\, Mielg
 o A. Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Re
 stores the Antitumour Immune Response Against Metastatic Melanoma. Front I
 mmunol. 2018 May 23\;9:1132. doi: 10.3389/fimmu.2018.01132.\n\n2) Figueire
 do CR\, Kalirai H\, Sacco JJ\, Azevedo RA\, Duckworth A\, Slupsky JR\, Cou
 lson JM\, Coupland SE. Loss of BAP1 expression is associated with an immun
 osuppressive microenvironment in uveal melanoma\, with implications for im
 munotherapy development. J Pathol. 2020 Apr\;250(4):420-439. doi: 10.1002/
 path.5384.\n\n3) Matareed M\, Maranou E\, Koskela SA\, Mehmood A\, Kalirai
  H\, Coupland SE\, Figueiredo CR.   Novel prognostication biomarker adip
 ophilin reveals a metabolic shift in uveal melanoma and new therapeutic op
 portunities. J Pathol. 2023 Jun\;260(2):203-221. doi: 10.1002/path.6076.\n
 \n4) Wang MM\, Coupland SE\, Aittokallio T\, Figueiredo CR. Resistance to 
 immune checkpoint therapies by tumour-induced T-cell desertification and e
 xclusion: key mechanisms\, prognostication and new therapeutic opportuniti
 es. Br J Cancer. 2023 Oct\;129(8):1212-1224. doi: 10.1038/s41416-023-02361
 -4.\n\n5) Langguth M\, Maranou E\, Koskela SA\, Elenius O\, Kallionpää R
 E\, Birkman EM\, Pulkkinen OI\, Sundvall M\, Salmi M\, Figueiredo CR.  TI
 MP-1 is an activator of MHC-I expression in myeloid dendritic cells with i
 mplications for tumor immunogenicity. Genes Immun. 2024 Jun\;25(3):188-200
 . doi: 10.1038/s41435-024-00274-7.
END:VEVENT
BEGIN:VTIMEZONE
TZID:Europe/Helsinki
X-LIC-LOCATION:Europe/Helsinki
BEGIN:STANDARD
DTSTART:19690101T000000
TZOFFSETFROM:+0200
TZOFFSETTO:+0200
TZNAME:EET
END:STANDARD
END:VTIMEZONE
END:VCALENDAR